BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 17360873)

  • 1. Tafenoquine for the treatment of recurrent Plasmodium vivax malaria.
    Kitchener S; Nasveld P; Edstein MD
    Am J Trop Med Hyg; 2007 Mar; 76(3):494-6. PubMed ID: 17360873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.
    Walsh DS; Looareesuwan S; Wilairatana P; Heppner DG; Tang DB; Brewer TG; Chokejindachai W; Viriyavejakul P; Kyle DE; Milhous WK; Schuster BG; Horton J; Braitman DJ; Brueckner RP
    J Infect Dis; 1999 Oct; 180(4):1282-7. PubMed ID: 10479159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
    Srivastava HC; Sharma SK; Bhatt RM; Sharma VP
    Indian J Malariol; 1996 Dec; 33(4):173-9. PubMed ID: 9125831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of monthly tafenoquine for prophylaxis of Plasmodium vivax and multidrug-resistant P. falciparum malaria.
    Walsh DS; Eamsila C; Sasiprapha T; Sangkharomya S; Khaewsathien P; Supakalin P; Tang DB; Jarasrumgsichol P; Cherdchu C; Edstein MD; Rieckmann KH; Brewer TG
    J Infect Dis; 2004 Oct; 190(8):1456-63. PubMed ID: 15378438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute vivax malaria with tafenoquine.
    Nasveld P; Kitchener S
    Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):2-5. PubMed ID: 15550254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloroquine sensitivity of Plasmodium vivax in Thailand.
    Looareesuwan S; Wilairatana P; Krudsood S; Treeprasertsuk S; Singhasivanon P; Bussaratid V; Chokjindachai W; Viriyavejakul P; Chalermrut K; Walsh D S; White J
    Ann Trop Med Parasitol; 1999 Apr; 93(3):225-30. PubMed ID: 10562823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
    Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
    Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia.
    Alvarez G; Piñeros JG; Tobón A; Ríos A; Maestre A; Blair S; Carmona-Fonseca J
    Am J Trop Med Hyg; 2006 Oct; 75(4):605-9. PubMed ID: 17038680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
    Sharma R; Sharma H; Jones S; Borghini-Fuhrer I; Domingo GJ; Gibson RA; Rolfe K; Tan L; Fiţa IG; Chen C; Bird P; Pingle A; Duparc S
    Malar J; 2024 May; 23(1):145. PubMed ID: 38741094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand.
    Vijaykadga S; Rojanawatsirivej C; Congpoung K; Wilairatana P; Satimai W; Uaekowitchai C; Pumborplub B; Sittimongkol S; Pinyorattanachote A; Prigchoo P
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):566-9. PubMed ID: 15689067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment].
    Telgt DS; Mulder L; Dolmans WM
    Ned Tijdschr Geneeskd; 1997 Sep; 141(37):1783-6. PubMed ID: 9545728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical curative efficacy of five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India.
    Yadav RS; Ghosh SK
    J Parasitol; 2002 Oct; 88(5):1042-4. PubMed ID: 12435158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
    Edstein MD; Walsh DS; Eamsila C; Sasiprapha T; Nasveld PE; Kitchener S; Rieckmann KH
    Med Trop (Mars); 2001; 61(1):56-8. PubMed ID: 11584657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
    N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand.
    Hamedi Y; Safa O; Zare S; Tan-ariya P; Kojima S; Looareesuwan S
    Southeast Asian J Trop Med Public Health; 2004 Sep; 35(3):570-4. PubMed ID: 15689068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping.
    Beck HP; Wampfler R; Carter N; Koh G; Osorio L; Rueangweerayut R; Krudsood S; Lacerda MV; Llanos-Cuentas A; Duparc S; Rubio JP; Green JA
    J Infect Dis; 2016 Mar; 213(5):794-9. PubMed ID: 26500351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.
    Fukuda MM; Krudsood S; Mohamed K; Green JA; Warrasak S; Noedl H; Euswas A; Ittiverakul M; Buathong N; Sriwichai S; Miller RS; Ohrt C
    PLoS One; 2017; 12(11):e0187376. PubMed ID: 29121061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    Rajapakse S; Rodrigo C; Fernando SD
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.